The influence of iPS-inducing factors NANOG and KLF4 in the prognosis of patients with breast cancer.
The influence of iPS-inducing factors NANOG and KLF4 in the prognosis of patients with breast cancer.
复制标题
DOI：
10.1200/jco.2011.29.27_suppl.230
复制
发表时间：
2011-09
期刊：
影响因子：
--
通讯作者：
T. Nagata
中科院分区：
文献类型：
--
作者：
T. Nagata
230背景：iPS细胞诱导因子(Oct3/4、Sox2、Klf4、c-Myc和Nanog)被报道不仅存在于胚胎干细胞，而且存在于正常细胞或癌细胞，包括乳腺癌。采用免疫组织化学方法检测iPS诱导因子在人乳腺癌标本中的表达，并分析其与术后复发和预后的相关性。方法对66例手术治疗的乳腺癌患者的临床资料进行分析。用组织芯片免疫组织化学方法检测c-myc、KLF4、NANOG、OCT4、SOX2的表达。结果患者平均年龄56.4岁(36~87岁)，晚期乳腺癌2期以上44例(66%)。激素受体阳性(HR+)53例(80%)，HER2阳性6例(9%)，三阴性(TN)7例(11%)。术后复发者16例(24%)，死亡6例(9%)。术后平均生存时间80.7个月(4~162个月)。NANOG高表达组的无瘤生存率(p=0.045)和总生存率(p<；0.0001)均低于低表达组。另一方面，KLF4高表达组的无瘤生存率高于低表达组(p=0.028)。结论NANOG的高表达是乳腺癌患者的预后因素，而KLF4的高表达与乳腺癌患者的预后负相关。提示NANOG增强乳腺癌细胞的生长和转移活性，而KLF4则降低这些活性。
230 Background: iPS cell-inducing factors (Oct3/4, Sox2, Klf4, c-Myc, and Nanog) are reported that they appears not only in ES cells (embryonic stem cell), but also in normal cell or carcinoma cell, including breast carcinoma. We evaluated the expression of iPS inducing factors in the human breast cancer specimen with immunohistochemistry, and analyze the relativity of the relapse and the prognosis after the operation. METHODS 66 cases of breast cancer that were performed the surgical operation in this department were examined. Expression of c-MYC, KLF4, NANOG, OCT4, and SOX2 were determined by immunohistochemistry of tissue microarray. RESULTS The average of the patient's age was 56.4 years old (36-87), and the advanced breast cancers in stage 2 or more were 44 cases (66%). About the hormone receptor and the HER2 appearance, hormone receptor-positive (HR+) types were 53 cases (80%), 6 cases (9%) were HER2-positive (HER2+) type, and 7 cases (11%) were triple-negative (TN) type. During the following period from operation, the relapse was found in 16 cases (24%), and six cases (9%) died. The average of survival time after the operation was 80.7 months (4-162). Patients with high expression group of NANOG had poor disease-free survival (p = 0.045) and overall survival (p < 0.0001) than those with low expression group. On the other hand, patients with high expression group of KLF4 had better disease-free survival (p = 0.028) than low expression group. CONCLUSIONS High expression of NANOG was prognostic factor, but KLF4 was inversely related to prognosis in breast cancer patients. It was suggested that NANOG increased the growth and metastatic activities of breast cancer cells, while KLF4 decreased these activities.